Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

卡培他滨 医学 内科学 探索性分析 随机对照试验 化疗 辅助化疗 佐剂 肿瘤科 外科 临床研究阶段 阶段(地层学) 随机化 癌症 疾病 临床试验 梅德林 多元分析 临床终点
作者
John A. Bridgewater,Peter Fletcher,Daniel H. Palmer,Hassan Z. Malik,Raj Prasad,Darius Mirza,Alan Anthony,Pippa G. Corrie,Stephen Falk,Meg Finch-Jones,Harpreet Singh Wasan,Paul J. Ross,Lucy Wall,Jonathan Wadsley,Thomas R. Evans,Deborah D. Stocken,Clive Stubbs,Raaj Praseedom,Yuk Ting Ma,Brian Ritchie Davidson
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (18): 2048-2057 被引量:237
标识
DOI:10.1200/jco.21.02568
摘要

PURPOSE The BILCAP study described a modest benefit for capecitabine as adjuvant therapy for curatively resected biliary tract cancer (BTC), and capecitabine has become the standard of care. We present the long-term data and novel exploratory subgroup analyses. METHODS This randomized, controlled, multicenter, phase III study recruited patients age 18 years or older with histologically confirmed cholangiocarcinoma or muscle-invasive gallbladder cancer after resection with curative intent and an Eastern Cooperative Oncology Group performance status of < 2. Patients were randomly assigned 1:1 to receive oral capecitabine (1,250 mg/m2 twice daily on days 1-14 of a 21-day cycle, for eight cycles) or observation. The primary outcome was overall survival (OS). This study is registered with EudraCT 2005-003318-13. RESULTS Between March 15, 2006, and December 4, 2014, 447 patients were enrolled; 223 patients with BTC resected with curative intent were randomly assigned to the capecitabine group and 224 to the observation group. At the data cutoff of January 21, 2021, the median follow-up for all patients was 106 months (95% CI, 98 to 108). In the intention-to-treat analysis, the median OS was 49.6 months (95% CI, 35.1 to 59.1) in the capecitabine group compared with 36.1 months (95% CI, 29.7 to 44.2) in the observation group (adjusted hazard ratio 0.84; 95% CI, 0.67 to 1.06). In a protocol-specified sensitivity analysis, adjusting for minimization factors, nodal status, grade, and sex, the OS hazard ratio was 0.74 (95% CI, 0.59 to 0.94). We further describe the prognostic impact of R status, grade, nodal status, and sex. CONCLUSION This long-term analysis supports the previous analysis, suggesting that capecitabine can improve OS in patients with resected BTC when used as adjuvant chemotherapy after surgery and should be considered as the standard of care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
保守派帮主完成签到,获得积分10
刚刚
AK完成签到,获得积分10
刚刚
老妖怪完成签到,获得积分10
1秒前
1秒前
3秒前
4秒前
Jasper的应助被温白开采纳,获得10
4秒前
英俊的铭的应助被linlianhao采纳,获得10
4秒前
小马甲的应助被小懿采纳,获得10
5秒前
5秒前
9465426发布了新的文献求助30
5秒前
iceanbecky发布了新的文献求助10
6秒前
打打的应助被风清扬采纳,获得10
6秒前
任性玫瑰发布了新的文献求助10
6秒前
hmhu完成签到,获得积分10
7秒前
7秒前
欧耶完成签到,获得积分20
7秒前
7秒前
回望发布了新的文献求助10
7秒前
xiaofeixia完成签到 ,获得积分10
8秒前
answer答案完成签到,获得积分10
8秒前
稳稳完成签到,获得积分10
9秒前
56455完成签到,获得积分10
10秒前
iNk的应助被Fantaro采纳,获得10
10秒前
LJH发布了新的文献求助10
10秒前
Qiao发布了新的文献求助10
10秒前
keibinn完成签到 ,获得积分10
11秒前
额特别发布了新的文献求助10
11秒前
12秒前
12秒前
12秒前
David发布了新的文献求助10
12秒前
巧克力发布了新的文献求助10
13秒前
13秒前
DW的应助被细心的凡蕾采纳,获得10
13秒前
NexusExplorer的应助被别梦寒采纳,获得10
14秒前
清秀语蝶的应助被zsy采纳,获得10
14秒前
NexusExplorer的应助被Www采纳,获得10
15秒前
脑洞疼的应助被111采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067